Dubai, UAE – July 14, 2025 – (SeaPRwire) – BlockBits, crypto futures trading platform, launch a new tool for advanced futures trading for higher potential returns with up to 200x leverage.
As cryptocurrency markets mature and price swings become more extreme, active traders are increasingly turning to risk management strategies once reserved for traditional finance. One strategy gaining notable traction is hedging – protecting open positions by opening an opposing trade to balance potential losses.
Unlike in stocks or commodities, hedging in crypto has only recently become practical for a wider range of traders. With the expansion of futures and perpetual contracts, traders can now offset price movements without selling or transferring their core holdings – a key advantage for long-term investors facing short-term market uncertainty.
“For example, a trader holding a major crypto asset can hedge against sudden volatility by opening a short futures position. If the asset’s price drops, gains from the short can help offset losses on the original holding – providing greater peace of mind in unpredictable conditions”, – said in company.
Recognizing this growing need, several crypto exchanges are now integrating built-in hedging tools. Features such as the ability to hold both long and short positions on the same pair within a single account are making once-complex strategies more accessible. This is especially important for traders using high leverage or delta-neutral approaches, where profits and losses on opposite positions can balance each other out.
Such tools also reduce trading costs by avoiding the need to close and reopen positions repeatedly – a process that can rack up fees and slippage in fast-moving markets. A smoother, single-interface experience means traders can react faster to market shifts without interrupting their broader investment plans.
One platform at the forefront of this trend is BlockBits, which has designed its trading environment specifically with hedging in mind. Users can open long and short positions simultaneously on the same pair, track risk and margin separately, and monitor real-time profit/loss and liquidation levels across both sides. In a recent example with the ETH/USDT pair, BlockBits traders were able to hold dual up to 200× leverage positions – a feature not always offered by other exchanges.
By integrating hedging into the core trading interface, platforms like BlockBits are helping crypto derivatives mature – providing tools that cater to both aggressive trading and robust risk management. As more traders seek to balance exposure without sacrificing opportunity, such innovations are set to become a standard part of the crypto futures landscape.
Contact information
Brand: BlockBits
Contact: Media team
E-mail: info@blockbitstech.com
Website: https://blockbitstech.com/en
SINGAPORE, July 14, 2025 - (ACN Newswire via SeaPRwire.com) - For Singaporeans envisioning buying a residential property abroad, the Global Property Expo organised by JLL (NYSE: JLL) offers an unparalleled opportunity to embark on that journey. This premier exhibition, dedicated to international real estate investment, will open its doors from Friday, July 18, to Sunday, July 20, 2025, from 10:00 AM to 8:00 PM daily at B2, Sands Expo & Convention Centre. Attendance at the Expo is free of charge. Filled with talks and over 30 exhibitors, numerous expert and specialist advisors, the Global Property Expo is an indispensable platform for anyone considering a residential property purchase beyond Singapore's shores.Why Attend? Your Global Residential Property Search Starts Here.The Global Property Expo is meticulously curated to provide Singaporean buyers with all the tools and insights needed to navigate the complexities of overseas residential property ownership.See Properties from Across the World on the Exhibition Floor (30+ Exhibitors)As the most expansive international residential property show ever held in Singapore, potential buyers can discover a wide array of international residential properties and related services, representing a truly global showcase with offerings from more than 20 countries.Properties on exhibit span Bali to Bangkok, Lisbon to London, Dubai to Abu Dhabi, Perth to Auckland, Tokyo to Boston, and far beyond. Among the highlights, DAMAC Properties will showcase a curated selection of its signature waterfront developments, including Canal Crown, Altitude, Canal Heights, Canal Heights II, Couture by Cavalli, DAMAC Bay, DAMAC Bay 2, and DAMAC Casa.ThirdHome will officially launch its presence in Asia at the Global Property Expo, bringing to the fore property ownership possibilities all over the world with a new investment model. 3 Days of Learning Opportunities The Global Property Expo features talks on stage in the centre of the Exhibition from 11:00 AM to 6:30 PM daily. The Opening Ceremony at 11:00 AM on Friday, 18 July 2025 features a keynote address delivered by Adam Challis, who leads UK Research & Strategy at JLL, offering invaluable market foresight.Learn how technology is democratising property ownership with tokenised buying, membership models, and more. And, don’t miss the Live-Streamed Closing Panel: "Buyers’ Toolkit: Your Next Steps to Owning Property Abroad" on Sunday at 6:00 PM. This live-streamed panel will distil the most actionable advice from across the conference into a practical checklist for prospective buyers, from due diligence and financing to legal considerations and post-purchase management.Specialist Expertise On-SiteAttendees can engage directly with a comprehensive array of professionals. Developers will showcase their projects, while legal advisors will clarify international property laws, and mortgage advisors will guide you through financing options. Furthermore, property ownership can be a passport to residency. Immigration specialists will be on hand to discuss residency considerations linked to property purchase. This unparalleled access to experts ensures all your questions are answered under one roof.The Global Property Expo is an essential event for any Singaporean contemplating a residential property investment overseas, providing a comprehensive platform for education, expert advice, and direct access to a world of real estate opportunities.Register now at www.globalpropertyexpo.comAbout JLLFor over 200 years, JLL (NYSE: JLL), a leading global commercial real estate and investment management company, has helped clients buy, build, occupy, manage and invest in a variety of commercial, industrial, hotel, residential and retail properties. A Fortune 500 company with annual revenue of $23.4 billion and operations in over 80 countries around the world, our more than 112,000 employees bring the power of a global platform combined with local expertise. Driven by our purpose to shape the future of real estate for a better world, we help our clients, people and communities SEE A BRIGHTER WAYSM. JLL is the brand name, and a registered trademark, of Jones Lang LaSalle Incorporated. For further information, visit jll.com.Strategic Partner: About Leading Real Estate Companies of the World®Chicago-based Leading Real Estate Companies of the World® (LeadingRE.com) is a global network of top independent real estate firms, with 550 companies and 134,000 sales associates in over 70 countries. LeadingRE supports its members with powerful connections to other market leaders and access to innovative, performance-driven programs. Its online learning platform, LeadingRE Institute, was named to Training magazine’s Top 10 Hall of Fame. LeadingRE also operates RELO Direct®, Inc. (RELODirect.com), its full-service relocation management company providing mobility services for corporate and government clients; and Luxury Portfolio International® (LuxuryPortfolio.com), its luxury marketing division, which markets approximately 50,000 luxury homes annually. LeadingRE is also active in commercial real estate, with 200 firms in over 20 countries specializing in the commercial arena. The firm also has a strategic international project marketing program, Destinations by LeadingRE (DestinationsByLeadingRE.com).Notes to editors:Pre-event interviews with organisers and key stakeholders are available. Please contact Theodore below.Media are welcome to attend the Global Property Expo and may register at pressroom.globalpropertyexpo.com/accreditation.Please see the Appendix below for a full list of confirmed exhibitors and key topics.Stay up to date: sign up for email notifications at marketing@globalpropertyexpo.com. Follow Global Property Expo on Facebook, Instagram, or LinkedIn.Media Contact:media@globalpropertyexpo.com Theodore Woon, Director, PINPOINT PRWhatsApp/Telegram: +65 9155 3507 Email: theodore@pinpointpr.sgAppendixConfirmed exhibitors include leading names such as JLL, Barfoot & Thompson, British Land, DAMAC Properties Co. LLC, Destinations by LeadingRE, Devato, Chalegrove Properties Limited, Citrus Living, Crimson Education, EMAAR, ES-CON Japan Ltd, Far East Consortium, Finbar Group, GetGround, Gurner Group, Helios & America Mortgages, Hotel 101, HSBC, International Property Alerts, Leading Real Estate Companies in the World, Levella Global, Marjan, Mouana Luxury Villas Phuket, Richmind, The Boundary, ThirdHome, Tiger Brokers, Tropicana, UOB, and Vakson.The 3-day program is designed to demystify the process of buying abroad. Key topics include: Residential Investment 101: A Beginner’s Guide. How to choose the right agent and the pros and cons of renting versus owning; Current market trends and hotspots for buyers.Regional spotlights (Southeast Asia, Japan, Middle East, Australia-New Zealand, USA) with developers presenting their latest projects.Property technology innovations, including insights from Japanese VC MetaProp and local company PropNex.Alternative wealth-creation strategies: fractional ownership, tokenisation, and membership models. Hear from Samuel Lee of Fraxtor on 20 July at 12:00 PM, followed by a panel with experts from MetaProp and THIRDHOME, exploring how shared ownership and blockchain are reshaping luxury property access.Seasoned investor insights: Hear firsthand from experienced investors on critical aspects like "My First Property Abroad: What I Wish I Knew" and "How HNWIs Are Building Passive Income Across Borders," providing practical lessons from those who have successfully diversified their portfolios.Luxury Real Estate & Branded Properties: What premium means in practice.Eco, Sustainability, Purpose, and Impact Investment. Copyright 2025 ACN Newswire via SeaPRwire.com.
KAWASAKI, Japan, July 14, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited today announced that one of its Fujitsu Uvance solutions that optimizes customers' global supply chains using specialized AI agents has been selected by the World Economic Forum's (WEF) AI Governance Alliance as one of 18 global advanced AI solutions that are transforming business. An independent, cross-industry group of AI leaders worldwide participated in selecting the solutions for the MINDS Programme from hundreds of applications. Applications were anonymized, and the final selection was based on cases that were implemented in actual settings and that have already achieved concrete results. The MINDS Programme (Meaningful, Intelligent, Novel, Deployable Solutions) was launched by WEF to spotlight AI applications already delivering real impact across critical sectors like healthcare, energy and financial services.Developed on the "Fujitsu Data Intelligence PaaS (1)" all-in-one operation platform offered under the Fujitsu Uvance business model to solve societal issue, the solution transforms inventory management and ordering operations in the supply chain and supports advanced management decision-making. The "Fujitsu Kozuchi AutoML" AI service, which can rapidly generate high-precision machine learning models, creates dozens of demand forecasting models in minutes from data automatically gathered and ordered using a knowledge graph. The solution employs multiple AI agents specialized for tasks such as procurement, inventory, production, and sales. Based on real-time alerts for inventory shortages or excess inventory, each AI agent develops countermeasures such as changing suppliers or allocating inventory. From the proposed countermeasures, the orchestrator agent selects the best option considering the balance of cost, lead time, and risk, and the evaluator agent assesses its validity, enabling users to quickly take optimal action based on proposals made by AI.A simulation carried out using data from an imagined major company with approximately US$10 billion in annual sales, showed the solution reducing annual inventory management costs by approximately US$15 million and cutting unnecessary inventory stock by approximately US$20 million, in addition to reducing work hours by more than 50%. The solution was also able to carry out an operating profit impact assessment following a simulated natural disaster within 3 hours of its occurrence. Fujitsu provides this solution to manufacturing customers facing inventory management challenges, supporting supply chain efficiency and resilience enhancement. Moving forward, Fujitsu will continue to assist its customers in making optimal decisions to swiftly respond to unforeseen events such as geopolitical risks, natural disasters, and market fluctuations. Under Fujitsu Uvance, Fujitsu will leverage Decision Intelligence utilizing data and AI to strengthen sustainability in the face of supply chain uncertainty, advancing both corporate value creation and social contribution.(1) Fujitsu Data Intelligence PaaS : Fujitsu's platform service that securely integrates and stores structured and unstructured data dispersed inside and outside the enterprise, and builds a high-speed data analysis infrastructure while ensuring governance. By combining advanced AI technology, it is possible to quickly analyze integrated and stored data and derive information necessary for decision-making in real time.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsu.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2025 JCN Newswire via SeaPRwire.com.
TOKYO, July 14, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has launched “URECE®” (brand name in China: “Youlesi®”, generic name: dotinurad) in China as a treatment for Gout. URECE was approved by the National Medical Products Administration in China as a treatment for gout patients with hyperuricemia in December 2024.URECE is a new therapeutic medicine for gout and hyperuricemia discovered by FUJI YAKUHIN. It suppresses uric acid reabsorption and lowers blood uric acid levels by selectively inhibiting the urate transporter (URAT1) related to reabsorption of uric acid in the kidney.Eisai concluded a license agreement with FUJI YAKUHIN for China and five ASEAN member states: Indonesia, Malaysia, Myanmar, the Philippines, and Thailand, granting exclusive development and distribution rights in these countries. This approval in China is based on the results of a multicenter, active controlled, double-blind, parallel-group, randomized, Phase 3 study of 451 gout patients conducted in China by Eisai.1 The results of this study showed that the proportion of subjects with serum uric acid levels of 6.0mg/dL or less at 24 weeks, which was the primary endpoint, was 73.6% [95% confidence interval (CI): 67.8,79.5] in the dotinurad group and 38.1% [95% CI: 31.6, 44.5] in the comparator febuxostat group, confirming the statistical superiority of dotinurad 4 mg over febuxostat 40 mg (difference of proportion 35.87% [95%CI: 27.36, 44.37, p less than 0.001]) (see section 3. About the Phase 3 Clinical Trial”). Eisai has obtained approval for dotinurad in China, Thailand and the Philippines.Gout can develop at any age, is more common in men than women, and during an acute attack, can cause severe joint pain, swelling, redness, and inflammation. The pain gradually improves over a few days, but can sometimes last for weeks. If left untreated, the joint tissue may become damaged and deformed, leading to restrictions in daily activities and a decrease in quality of life.2The prevalence of gout is increasing, and it is estimated that there are currently about 23 million patients with gout in China.3 It is expected that the number of patients will further increase in the near future due tochanges in lifestyle and dietary preferences in accordance with socioeconomic development. Eisai is committed to providing URECE to more patients with gout in China as a new treatment option, and will contribute to improving the quality of life (QOL) of patients.“Youlesi®”Product OutlineChinese Trade name: “Youlesi” (URECE)Chinese generic name: Duo ti nuo lei pian (Dotinurad Tablets)Indication for use: It is indicated for gout patients with hyperuricemia.Dosage and administration: For oral use, the usual adult initial dosage is 1 mg of dotinurad once daily. The dose level should then be gradually increased as needed by checking blood uric acid levels. The usual maintenance dosage is 2mg once daily and may be adjusted according to the patient’s condition, but up to 4 mg once dailyAbout “URECE®” (Dotinurad)URECE is a therapeutic medicine for gout and hyperuricemia discovered by FUJI YAKUHIN. URECE selectively inhibits URAT1, one of the uric acid transporters, thus preventing reabsorption of uric acid by the kidneys and promoting uric acid excretion in the urine. In addition, URECE has a small effect on other transporters affecting uric acid secretion, so it reduces serum uric acid levels at lower doses. URECE is expected to have a low risk of side effects and drug interactions. In Japan, FUJI YAKUHIN obtained manufacturing and marketing approval for URECE in January 2020 and launched it in May 2020.Eisai concluded a license agreement with FUJI YAKUHIN for China and five ASEAN member states: Indonesia, Malaysia, Myanmar, the Philippines, and Thailand, granting exclusive development and distribution rights in these countries. URECE was approved in Thailand for gout and hyperuricemia in Thailand in September, 2024 and in the Philippines in February, 2025.About the Phase 3 Clinical Trial (Study FYU-981-J086-301)1This was a multicenter, active-controlled, double-blind, parallel-group, randomized, Phase 3 study conducted to confirm the superiority of dotinurad 4 mg over febuxostat 40 mg as the primary endpoint, assess safety, and confirm the noninferiority of dotinurad 2 mg to febuxostat 40 mg as the secondary endpoint in Chinese patients with gout. Patients with gout and serum uric acid (SUA) levels exceeding 7.0 mg/dL were randomly assigned to either the dotinurad group or the febuxostat group in a 1:1 ratio, investigational product treatment for 24 weeks (the dotinurad group received 1 mg/day for 4 weeks, 2 mg/day for 8 weeks, and 4 mg/day for 12 weeks, while the febuxostat group received 20 mg/day for 4 weeks and 40 mg/day for 20 weeks). The primary endpoint was the proportion of patients with SUA less than or equal to 6.0 mg/dL at 24 weeks, and the secondary endpoint was the proportion of patients with SUA less than or equal to 6.0 mg/dL at 12 weeks.Of the total 451 patients, 225 were assigned to the dotinurad group and 226 to the febuxostat group. Of these, 441 patients (220 in the dotinurad group and 221 in the febuxostat group) were included in the Full Analysis Set (FAS). For the primary endpoint, the proportion of patients with SUA less than or equal to 6.0 mg/dL at 24 weeks was 73.6% [95% confidence interval (CI): 67.8, 79.5] in the dotinurad group and 38.1% [95% CI: 31.6, 44.5] in the febuxostat group, confirming the statistical superiority of dotinurad 4 mg over febuxostat 40 mg (difference of proportion 35.87% [95% CI: 27.36, 44.37, p less than 0.001]).For the secondary endpoint, the proportion of patients with SUA less than or equal to 6.0 mg/dL at 12 weeks was 55.5% in the dotinurad group and 50.5% in the febuxostat group, confirming the statistical non-inferiority of dotinurad 2 mg to febuxostat 40mg (difference of proportion 5.24% [95% CI: -3.69, 14.17]).The most common adverse events were gouty arthritis, COVID-19, and liver function abnormality in the dotinurad group, and gouty arthritis, COVID-19, and increased alanine aminotransferase (ALT) in the febuxostat group. No new safety concerns with dotinurad were observed.References1. Sun J, Wang Y, Zhang X, et al. POS0255 A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDYCOMPARING EFFICACY OF DOTINURAD AND FEBUXOSTAT FOR THE TREATMENT OF GOUT IN CHINESESUBJECTS. Annals of the Rheumatic Diseases 2024;83:407-408.2. Huang, J., Ma, Z.F., Tian, Y. et al. Epidemiology and Prevalence of Gout in Mainland China: an Updated Systematic Review and Meta-Analysis. SN Compr. Clin. Med. 2, 1593–1606 (2020).3. Estimated data calculated from reference 2 and United Nations World Population Estimates - World Population Prospects, URL: https://population.un.org/wpp/Media Inquiries:Eisai Co., Ltd.Public Relations DepartmentTEL: +81-(0)3-3817-5120 Copyright 2025 JCN Newswire via SeaPRwire.com.
